Overview

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Status:
Recruiting

Trial end date:
2022-09-20

Target enrollment:

Participant gender:

Summary

This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Medical University Fourth Hospital

Collaborators:

Beijing 302 Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.
The fifth medical center of PLA general hospital

Treatments:

Acivicin
Albumin-Bound Paclitaxel
Capecitabine
Carboplatin
Paclitaxel